Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.
Coombs J, McBurney C, Gondek K, Copley-Merriman C. Evidence of patient reported outcomes in labeling for oncology products: evaluation of United States and European labels. Mapi Quality of Life Newsletter. 2002 Oct;29:1-3.
Douillard JY, Skarin A, Baselga J, Natale R, Giaccone G, Maddox A, Heyes AE. Improvement in disease-related symptoms and quality of life (QOL) in patients treated with advanced non-small cell lung cancer (NSCLC) treated with zd1839 in ideal1 and ideal2. Poster presented at the European Society for Medical Oncology; October 2002. Nice, France.
Copley-Merriman K, Pawel J, Shepard F, Kimmel K, Gulyas S, Eckert S. Randomized phase 2 study of the oral histone deacetylase inhibitor ci-994 plus gemcitabine vs. placebo plus gemcitabine in second-line nsclc: health-related quality of life results. Poster presented at the American Society of Clinical Oncology; May 2002. Orlando, FL.
Lewis B, Silberman C, Heyes AE. Side effects of chemotherapy among patients with ovarian cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting; May 2002. Washington, DC.
Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.